Trelegy Ellipta is a Small Molecule owned by GSK, and is involved in 31 clinical trials, of which 19 were completed, 10 are ongoing, and 2 are planned.

Fluticasone furoate is a glucocorticoid agonist. Enhancement of eosinophil apoptosis or reversal of cytokine-induced eosinophil survival are reported to be one important mechanism by which glucocorticoids reduce eosinophil numbers. The basic mechanism of glucocorticoid actions is that they penetrate into the cell and bind to glucocorticoid receptor molecules in the cytoplasm. The glucocorticoid glucocorticoid receptor (GR) complex acts as a transcription factor, binding to specific DNA sites in the nucleus.

Umeclidinium is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation.

Vilanterol targets the beta2-adrenoceptor and agonize it. he pharmacological effects of beta2-adrenoceptor agonist drugs, stimulate intracellular adenyl cyclase, the enzyme that catalyses the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine mono phosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. Beta2-agonists work by attaching to the beta-receptors on bronchial smooth-muscle cells. Once this attachment occurs the receptor is activated, it causes relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, particularly from mast cells.

The revenue for Trelegy Ellipta is expected to reach a total of $62.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Trelegy Ellipta NPV Report.

Trelegy Ellipta is currently owned by GSK.

Trelegy Ellipta Overview

Fluticasone furoate, umeclidinium bromide and vilanterol trifenatate (Trelegy Ellipta / Elebrato Ellipta / Temybric Ellipta / Trelegy) is a fixed dose combination. It is formulated as dry powder inhaler for inhalation route of administration. It is indicated for the treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and also as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD)who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist. Trelegy Ellipta is indicated for the maintenance treatment of asthma in patients aged 18 years and older.

Trelegy Ellipta is under development for the treatment of asthma in Japan.

GSK Overview

GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

The company reported revenues of (British Pounds) GBP34,114 million for the fiscal year ended December 2021 (FY2021), an increase of 0% over FY2020. In FY2021, the company’s operating margin was 18.1%, compared to an operating margin of 22.8% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 16.9% in FY2020. The company reported revenues of GBP7,829 million for the third quarter ended September 2022, an increase of 13% over the previous quarter.

Quick View – Trelegy Ellipta

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Trelegy Ellipta
Administration Pathway
  • Inhalational
Therapeutic Areas
  • Respiratory
Key Companies
  • Sponsor Company: GSK
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.